Skip to main content
SpringerLink
Log in

Silodosin: a guide to its use in benign prostatic hyperplasia

  • Clinical Questions & Answers on Drugs
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

The highly selective α1A-adrenergic receptor antagonist silodosin rapidly improves the signs and symptoms of benign prostatic hyperplasia (BPH). Oral silodosin is generally well tolerated in men with BPH, with a favourable cardiovascular tolerability profile. Abnormal ejaculation is the most commonly reported adverse effect associated with silodosin therapy; however, only 3.9% of patients discontinued treatment due to this event.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Curran MP. Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs 2011; 71(7): 897–907

    Article  PubMed  CAS  Google Scholar 

  2. Montorsi F. Profile of silodosin. Eur Urol 2010; 4 Suppl. 9: 491–5

    Google Scholar 

  3. Urorec 4 and 8 mg hard capsules: summmary of product characteristics. London: European Medicines Agency, 2011 Aug 3

  4. Rapaflo® (silodosin) capsules: US summary of prescribing information. Morristown (NJ): Watson Laboratories, Inc., 2009 Nov

  5. Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009 Jun; 181(6): 2634–40

    Article  PubMed  CAS  Google Scholar 

  6. Chapple CR, Montorsi F, Tammela TLJ. Silodosin therapy for lower urinary tract symptoms in men with suspect benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo-and active-controlled clinical trial performed in Europe. Eur Urol 2011; 59: 342–52

    Article  PubMed  CAS  Google Scholar 

  7. CHMP assessment report for Urorec (international nonproprietary name: silodosin; procedure no. EMEA/H/C/001092). London: European Medicines Agency, 2010 Jan 10

  8. Roehrborn CG, Kaplan SA, Lepor H, et al. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis 2011 Jun; 14(2): 143–8

    Article  PubMed  CAS  Google Scholar 

  9. Marks LS, Gittelman MC, Hill LA, et al. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 2009 Dec; 74(6): 1318–22

    Article  PubMed  Google Scholar 

  10. Kaplan SA. Side effects of α-blocker use: retrograde ejaculation. Rev Urol 2009 Fall; 11 Suppl. 1: S14–8

    PubMed  Google Scholar 

  11. Lepor H, Hill LA. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy 2010 Dec; 30(12): 1303–12

    Article  PubMed  CAS  Google Scholar 

  12. Silodosin 4 mg, 8 mg capsules; summary of clinical safety. Milan: Recordati, 2009. (Data on file)

Download references

Acknowledgements and Disclosure

This review was updated from Drugs 2011; 71 (7): 897–907[1] and was reviewed by S. Gravas, Department of Urology, University Hospital of Larissa, Larissa, Greece; R. Janknegt, Department of Clinical Pharmacy and Toxicology, Maasland Ziekenhuis, Sittard, the Netherlands; T. Schneider, Praxisklinik Urologie Rhein-Ruhr, Mülheim, Germany.

The preparation of these articles was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Gillian M. Keating & Monique P. Curran

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monique P. Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, G.M., Curran, M.P. Silodosin: a guide to its use in benign prostatic hyperplasia. Drugs Ther Perspect 28, 1–4 (2012). https://doi.org/10.2165/11606250-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11606250-000000000-00000

Keywords

Search

Navigation